Rennova Health CEO and leadership

Thomas Mika previously served as the Chairman of the Board of Rennova Health, the successor company to CollabRx and its predecessor, Tegal Corporation, a semiconductor capital equipment company. On the Board of Directors of Tegal since its spin-out from Motorola in 1989, Mika assumed the roles of Chief Financial Officer in 2002, CEO in 2005 and Chairman & CEO in 2006, positions which he held until 2015. In 2015, Tegal merged with Rennova Health with Mika retaining the position of Chairman until joining POET in November 2016. Previously, Mika co-founded IMTEC, a boutique investment and consulting firm, serving clients in the U.S., Europe and Japan over a period of 20 years, taking on the role of CEO in several ventures. Earlier in his career, Mika was a managing consultant with Cresap, McCormick & Paget and a policy analyst for the National Science Foundation. He holds a Bachelor of Science in Microbiology from the University of Illinois at Urbana-Champaign and a Master of Business Administration from the Harvard Graduate School of Business.

Currently the CEO of Rennova Health, Inc.More information at www.rennovahealth.comRestructured Medytox Solutions, Inc. in mid 2011 and oversaw the growth from less than $1M of sales per year to approximately $57M of reported sales in 2014. Completed merger with CollabRx, Inc. in 2015 to create Nasdaq listed Rennova Health, Inc. (RNVA) in November 2015. Redirected business model from diagnostics to rural hospital development and acquisition in 2017 after significant disruption in the diagnostics sector.Over 20 years’ experience in the development, restructuring, acquisition and management of startup and small companies in various sectors from alternative energy, oil and gas production and exploration, mining and healthcare. Provides services for both private and public companies. Has an extensive network of legal, accounting and other professional advisers that can be relied on to assist when required. Has numerous funding sources in different sectors to approach if required for qualifying projects. Has secured and structured millions of dollars in funding for various projects, including in excess of $30M in equity funding and approximately $20M of debt in 2015 and 2016 and a further $20M of investment in 2017. Main focus is acquisition and mergers of synergistic business with an emphasis on revenue and a sustainable business model to create long term value.

Jonathan Immordino is a Chief Financial Officer at RENNOVA HEALTH, INC..

Jonathan Jacoby is a COO at RENNOVA HEALTH, INC. and is based in Palo Alto, California.

Currently the CEO of Rennova Health, Inc.More information at www.rennovahealth.comRestructured Medytox Solutions, Inc. in mid 2011 and oversaw the growth from less than $1M of sales per year to approximately $57M of reported sales in 2014. Completed merger with CollabRx, Inc. in 2015 to create Nasdaq listed Rennova Health, Inc. (RNVA) in November 2015. Redirected business model from diagnostics to rural hospital development and acquisition in 2017 after significant disruption in the diagnostics sector.Over 20 years’ experience in the development, restructuring, acquisition and management of startup and small companies in various sectors from alternative energy, oil and gas production and exploration, mining and healthcare. Provides services for both private and public companies. Has an extensive network of legal, accounting and other professional advisers that can be relied on to assist when required. Has numerous funding sources in different sectors to approach if required for qualifying projects. Has secured and structured millions of dollars in funding for various projects, including in excess of $30M in equity funding and approximately $20M of debt in 2015 and 2016 and a further $20M of investment in 2017. Main focus is acquisition and mergers of synergistic business with an emphasis on revenue and a sustainable business model to create long term value.